Make an enquiry
Refer a patient
Pay my bill
0808 304 2332

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
GenesisCare - logo
Patients
Cancer care
Exploring cancer care
Bladder cancer
Head & neck cancer
Lung cancer
Prostate cancer
Bowel cancer
Kidney cancer
Non-Hodgkin's lymphoma
Skin cancer
Breast cancer
Leukaemia
Ovarian cancer
All cancers we treat
Diagnosis
Cancer diagnosis
Breast diagnostics
Prostate diagnostics
Diagnostic clinics
Pathology tests
Blood tests
Bone marrow test
Flexible cystoscopy
Imaging scans
CT scanning
MRI scanning
PET-CT scan
Prostate mpMRI scan
Treatments
Cancer treatments
Breast cancer
Prostate cancer
Pancreatic cancer
Lung cancer
Palliative
Radiotherapy
SABR
MRIdian
EBRT
IMRT
VMAT
Chemotherapy & SACTs
Hormone therapy
Targeted therapies
Immunotherapy
Theranostics
177Lutetium
Radium-223
Patient support
Patient resources
Glossary of medical terms
Helpful organisations
Going private
Paying for treatment
LGBTIQ+ cancer care
Cancer wellbeing blog
Breast cancer early signs
Checking for prostate cancer
Having cancer without knowing
Patient stories
Marco's journey
Diana's journey
Liz's journey
Integrative cancer care
Exercise medicine
Wellbeing services
Sleep support
About us
Who we are
Our Board
Contact us
Why choose GenesisCare
Governance and safety
About clinical trials
Current clinical trials
Careers
Our benefits
News
Our campaigns
Healthcare professionals
Oncology
Treatments
Radiotherapy
Chemotherapy & SACT's
Theranostics
Diagnostics
Diagnostic clinics
Diagnostic tests and scans
Integrative cancer care
Penny Brohn
Exercise medicine
Palliative treatments
Specialties
Breast oncology
Head & neck oncology
Prostate oncology
Research
Clinical trials
Clinical Publications
About us
Practising privileges
Clinician leads & governance
Access our services
Innovations blog
Resources
Breast Illustrations
Case Studies
MRIdian case studies
Head and neck case study
Diagnostics case study
Blood cancer case study
Governance
Find a centre
Find a doctor
GenesisCare - logo
0808 304 2332
Make an enquiry
Refer a patient
Pay my bill

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
Find a centre
Find a doctor
Patients
Cancer care
Exploring cancer care
Bladder cancer
Head & neck cancer
Lung cancer
Prostate cancer
Bowel cancer
Kidney cancer
Non-Hodgkin's lymphoma
Skin cancer
Breast cancer
Leukaemia
Ovarian cancer
All cancers we treat
Diagnosis
Cancer diagnosis
Breast diagnostics
Prostate diagnostics
Diagnostic clinics
Pathology tests
Blood tests
Bone marrow test
Flexible cystoscopy
Imaging scans
CT scanning
MRI scanning
PET-CT scan
Prostate mpMRI scan
Treatments
Cancer treatments
Breast cancer
Prostate cancer
Pancreatic cancer
Lung cancer
Palliative
Radiotherapy
SABR
MRIdian
EBRT
IMRT
VMAT
Chemotherapy & SACTs
Hormone therapy
Targeted therapies
Immunotherapy
Theranostics
177Lutetium
Radium-223
Patient support
Patient resources
Glossary of medical terms
Helpful organisations
Going private
Paying for treatment
LGBTIQ+ cancer care
Cancer wellbeing blog
Breast cancer early signs
Checking for prostate cancer
Having cancer without knowing
Patient stories
Marco's journey
Diana's journey
Liz's journey
Integrative cancer care
Exercise medicine
Wellbeing services
Sleep support
About us
Who we are
Our Board
Contact us
Why choose GenesisCare
Governance and safety
About clinical trials
Current clinical trials
Careers
Our benefits
News
Our campaigns
Healthcare professionals
Oncology
Treatments
Radiotherapy
Chemotherapy & SACT's
Theranostics
Diagnostics
Diagnostic clinics
Diagnostic tests and scans
Integrative cancer care
Penny Brohn
Exercise medicine
Palliative treatments
Specialties
Breast oncology
Head & neck oncology
Prostate oncology
Research
Clinical trials
Clinical Publications
About us
Practising privileges
Clinician leads & governance
Access our services
Innovations blog
Resources
Breast Illustrations
Case Studies
MRIdian case studies
Head and neck case study
Diagnostics case study
Blood cancer case study
Governance
Make an enquiry
Refer a patient
Pay my bill
0808 304 2332
  • Healthcare Professionals
  • Resources
  • Case studies
  • Head and neck case study

Head and neck cancer case study

A case study of chemoradiotherapy following transoral surgery to treat tonsil cancer

Case study

Chemoradiotherapy following transoral surgery to treat tonsil cancer

Dr. Nicola Dallas

image

She has a special interest in technical radiotherapy and introduced the use of intensity modulated radiotherapy (IMRT) and now dynamic arc IMRT for the treatment of head & neck cancers to the centre.

View profile

Case presentation

A 55-year-old male presented in clinic following a chest infection and persistent swelling of the left tonsil.

A neck MRI was requested and demonstrated a 27mm x 15mm x 18mm left tonsil mass, with an associated enlarged left level 2a lymph node. A biopsy of the left tonsil confirmed p16 positive squamous cell carcinoma (SCC) and an FDG PET-CT identified the tonsil primary and associated cervical lymph node. Importantly there was no distant metastatic disease.

The diagnosis was subsequently confirmed as T2N1 p16 positive squamous cell carcinoma of the left tonsil.

The gentleman was otherwise completely fit and well, a non-smoker consuming in the range of 6-12 units of alcohol per week. He lived with his family and previously worked as a banker.

Challenges of presentation and choice of treatment

Initial discussion focused on two potential treatment plans.

Either primary chemoradiotherapy given with curative intent, or alternatively initial transoral laser surgery to remove the primary tumour, together with a neck dissection. Following MDT review the patient was referred to Prof. Stuart Winter, Consultant Head and Neck Surgeon, and the transoral laser surgery and neck dissection was agreed as the first intervention, to potentially enable a reduction in the intensity of the adjuvant treatment and subsequent toxicity.

Treatment

Post-operative assessment confirmed pT2 (30mm) pN1 (25mm) with extracapsular extension p16 positive L tonsil SCC. The case was once again reviewed in the MDT and agreed for adjuvant chemoradiotherapy.

Volumetric modulated arc therapy (VMAT) was planned  65 / 60 / 54 Gy in 301 fractions to the left oropharynx and neck, together with weekly cisplatin chemotherapy. Each radiotherapy session involved a short period – just a few minutes – on the couch and the plan was delivered with curative intent.

The patient received this course of treatment at the GenesisCare outpatient centre in Windsor with the support of the dedicated head and neck multidisciplinary team. This included weekly consultant appointments, a nurse specialist, dietitian reviews and speech and language therapist (SALT) support.

The gentleman also opted for the complimentary exercise medicine course at GenesisCare in Windsor and received a personalised prescription to support his physical and mental strength and resilience.

He also received acupuncture and reflexology through our partnership with the cancer charity, Penny Brohn UK.

Side effects and management

The patient experienced side-effects, including a sore throat and mouth. These were managed with painkillers and mouth washes, together with alterations to his diet to softer and liquid foods that were less likely to sting. Other side effects such as a dry mouth, loss of taste, skin soreness and skin desquamation were all experienced, and lots of advice given on how best to manage them. They gradually resolved over time following the completion of radiotherapy.

By 12 weeks, the skin had healed, taste was recovering and he no longer needed painkillers. Although the patient still found spicy food challenging, he was able to eat all food textures.

Results and follow-up

Close clinical follow-up continued post treatment with weekly dietitian contact and monthly consultant appointments.

An FDG PET/CT, 12-weeks following the end of treatment, demonstrated a likely complete response with some persistent post treatment inflammation visible.

Further outcome measures will be assessed through validated PROMs collected during and post treatment.

The patient’s progress will continue to be monitored for up to five years f

image

1. T1 MRI axial slice showing left level 2a lymph node from left tonsil primary.

image

2. FDG PET-CT fused axial image showing left level 2a lymph node with left tonsil primary.

References

  1. RCR Radiotherapy dose fractionation, third edition 2019. BFCO(19)3
UK Genesis Logo

GenesisCare UK

Careers
Gender pay gap reports
UK tax strategy

Website policies

Privacy Information for Data Subjects
Patient terms and conditions
Modern slavery act transparency
Section 172 Statement by Directors
Cookie Preferences

Contact us

Make an Enquiry
Concerns, Comments, Complaints? (NHS patients)
Concerns, Comments, Complaints? (Private patients)

Media & Social

News Room - What's been happening
Facebook
X
Linkedin
Youtube
Vimeo

Copyright © 2024 GenesisCare. All Rights Reserved.

Genesis Cancer Care UK Limited (05796994) is incorporated in England & Wales and has its registered office at: Wilson House, Waterberry Drive, Waterlooville, Hampshire, PO7 7XX